Leukocytosis is a risk factor for recurrent arterial thrombosis in young patients with polycythemia vera and essential thrombocythemia

American Journal of Hematology

Volumn 85, Issue 2, 2010, Pages 97-100

  De Stefano, Valerio ^a   Za, Tommaso ^a   Rossi, Elena ^a   Vannucchi, Alessandro M ^b   Ruggeri, Marco ^c   Elli, Elena ^d   Micó, Caterina ^e   Tieghi, Alessia ^f   Cacciola, Rossella R ^g   Santoro, Cristina ^h   Gerli, Giancarla ⁱ   Guglielmelli, Paola ^b   Pieri, Lisa ^b   Scognamiglio, Francesca ^c   Rodeghiero, Francesco ^c   Pogliani, Enrico M ^d   Finazzi, Guido ^e   Gugliotta, Luigi ^f   Leone, Giuseppe ^a   Barbui, Tiziano ^e  

^a CATHOLIC UNIVERSITY   (Italy)

^b UNIVERSITY OF FLORENCE   (Italy)

^c SAN BORTOLO HOSPITAL   (Italy)

^d SAN GERARDO HOSPITAL   (Italy)

^e OSPEDALI RIUNITI   (Italy)

^f S MARIA NUOVA HOSPITAL   (Italy)

^g UNIVERSITY OF CATANIA   (Italy)

^h SAPIENZA UNIVERSITY OF ROME   (Italy)

ⁱ UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANAGRELIDE; ANTIVITAMIN K; BUSULFAN; HYDROXYUREA; INTERFERON; PIPOBROMAN;

ADULT; AGED; ARTERY THROMBOSIS; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DISEASE ASSOCIATION; FEMALE; HUMAN; LEUKOCYTE COUNT; LEUKOCYTOSIS; MAJOR CLINICAL STUDY; MALE; MESENTERIC VEIN THROMBOSIS; PATIENT SELECTION; POLYCYTHEMIA VERA; PRIORITY JOURNAL; PROBABILITY; PROGNOSIS; RECURRENT DISEASE; RETROSPECTIVE STUDY; RISK FACTOR; THROMBOCYTHEMIA;

ADOLESCENT; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; FEMALE; HUMANS; LEUKOCYTE COUNT; LEUKOCYTOSIS; MALE; MIDDLE AGED; POLYCYTHEMIA VERA; RETROSPECTIVE STUDIES; RISK FACTORS; THROMBOCYTHEMIA, ESSENTIAL; THROMBOSIS;

EID: 75449098063     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.21593     Document Type: Article

References (26)

1. Elliott MA, Tefferi A. Thrombosis and haemorrhage in polycythaemia vera and essential thrombocythaemia. Br J Haematol 2005;128:275-290.
2. Cortelazzo S, Viero P, Finazzi G, et al. Incidence and risk factors for thrombotic complications in a historical cohort of 100 patients with essential thrombocythemia. J Clin Oncol 1990;8:556-562.
3. Besses C, Cervantes F, Pereira A, et al. Major vascular complications in essential thrombocythemia: A study of the predictive factors in a series of 148 patients. Leukemia 1999;13:150-154.
4. Passamonti F, Rumi E, Pungolino E, et al. Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia. Am J Med 2004;117:755-761.
5. Marchioli R, Finazzi G, Landolfi R, et al. Vascular and neoplastic risk in a large cohort of patients with polycythemia vera. J Clin Oncol 2005;23:2224-2232.
6. Wolanskyj AP, Schwager SM, McClure RF, et al. Essential thrombocythemia beyond the first decade: Life expectancy, long-term complication rates, and prognostic factors. Mayo Clin Proc 2006;81:159-166.
7. Carobbio A, Finazzi G, Guerini V, et al. Leukocytosis is a risk factor for thrombosis in essential thrombocythemia: Interaction with treatment, standard risk factors and Jak2 mutation status. Blood 2007;109:2310-2313.
8. Gangat N, Strand J, Li CY, et al. Leucocytosis in polycythaemia vera predicts both inferior survival and leukaemic transformation. Br J Haematol 2007;138:354-358.
9. Landolfi R, Di Gennaro L, Barbui T, et al. Leukocytosis as a major thrombotic risk factor in patients with polycythemia vera. Blood 2007;109:2446-2452.
10. Tefferi A, Gangat N, Wolanskyj A. The interaction between leukocytosis and other risk factors for thrombosis in essential thrombocythemia. Blood 2007;109:4105.
11. Carobbio A, Antonioli E, Guglielmelli P, et al. Leukocytosis and risk stratification assessment in essential thrombocythemia. J Clin Oncol 2008;16:2732-2736.
12. Carobbio A, Finazzi G, Antonioli E, et al. Thrombocytosis and leukocytosis interaction in vascular complications of essential thrombocythemia. Blood 2008;112:3135-3137.
13. Caramazza D, Caracciolo C, Barone R, et al. Correlation between leukocytosis and thrombosis in Philadelphia-negative chronic myeloproliferative neoplasms. Ann Hematol 2009;88:967-971.
14. De Stefano V, Za T, Rossi E, et al. Recurrent thrombosis in patients with polycythemia vera and essential thrombocythemia: Incidence, risk factors, and effect of treatments. Haematologica 2008;93:372-380.
15. Grau AJ, Boddy AW, Dukovic DA, et al. Leukocyte count as an independent predictor of recurrent ischemic events. Stroke 2004;35:1147-1152.
16. Wheeler JG, Mussolino ME, Gillum RF, et al. Associations between differential leucocyte count and incident coronary heart disease: 1764 incident cases from seven prospective studies of 30,374 individuals. Eur Heart J 2004;25:1287-1292.
17. Ovbiagele B, Lynn MJ, Saver JL, et al., WASID Study Group. Leukocyte count and vascular risk in symptomatic intracranial atherosclerosis. Cerebrovasc Dis 2007;24:283-288.
18. Rana JS, Boekholdt SM, Ridker PM, et al. Differential leucocyte count and the risk of future coronary artery disease in healthy men and women: The EPIC-Norfolk Prospective Population Study. J Int Med 2007;262:678-689.
19. Harrison CN, Campbell PJ, Buck G, et al. Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. N Engl J Med 2005;353:33-45.
20. Campbell PJ, Scott LM, Buck G, et al. Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: A prospective study. Lancet 2005;366:1945-1953.
21. Falanga A, Marchetti M, Evangelista V, et al. Polymorphonuclear leukocyte activation and hemostasis in patients with essential thrombocythemia and polycythemia vera. Blood 2000;96:4261-4266.
22. Falanga A, Marchetti M, Vignoli A, et al. Leukocyte-platelet interaction in patients with essential thrombocythemia and polycythemia vera. Exp Hematol 2005;33:523-530.
23. Vannucchi AM, Antonioli E, Guglielmelli P, et al. Clinical profile of homozygous JAK2V617F 617V>F mutation in patients with polycythemia vera or essential thrombocythemia. Blood 2007;110:840-846.
24. Vannucchi AM, Antonioli E, Guglielmelli P, et al. Prospective identification of high-risk polycythemia vera patients based on JAK2 V617F allele burden. Leukemia 2007;21:1952-1959.
25. Dahabreh IJ, Zoi K, Giannouli S, et al. Is JAK2 V617F mutation more than a diagnostic index? A meta-analysis of clinical outcomes in essential thrombocythemia. Leuk Res 2009;33:67-73.
26. De Stefano V, Za T, Rossi E, et al. Influence of the JAK2 V617F mutation and inherited thrombophilia on the thrombotic risk among patients with essential thrombocythemia. Haematologica 2009;94:733-737.